TY - JOUR
T1 - IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays
AU - International Federation of Clinical Chemistry (IFCC) Task Force on Clinical Applications of Cardiac Bio-Markers
AU - Apple, Fred S.
AU - Jaffe, Allan S.
AU - Collinson, Paul
AU - Mockel, Martin
AU - Ordonez-Llanos, Jordi
AU - Lindahl, Bertil
AU - Hollander, Judd
AU - Plebani, Mario
AU - Than, Martin
AU - Chan, M. H.M.
N1 - Publisher Copyright:
© 2014 The Canadian Society of Clinical Chemists.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, with the purpose of providing evidence based educational materials to assist all biomarker users, i.e. laboratorians, clinicians, researchers, in-vitro diagnostics and regulatory agencies, in better understanding important analytical and clinical aspects of established and novel cardiac biomarkers for use in clinical practice and research. The goal of the task force was to promulgate the same information conjointly through the in vitro diagnostic industry to the laboratory, emergency department and cardiologists. The initial undertaking of the TF-CB, which is comprised of laboratory medicine scientists, emergency medicine physicians and cardiologists, was to address two key issues pertaining to implementing high-sensitivity cardiac troponin (hs-cTn) assays in clinical practice: the 99th percentile upper reference limit (URL) and calculating serial change values in accord with the Universal Definition of AMI. The highlights of both concepts from IFCC statements are described.
AB - In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, with the purpose of providing evidence based educational materials to assist all biomarker users, i.e. laboratorians, clinicians, researchers, in-vitro diagnostics and regulatory agencies, in better understanding important analytical and clinical aspects of established and novel cardiac biomarkers for use in clinical practice and research. The goal of the task force was to promulgate the same information conjointly through the in vitro diagnostic industry to the laboratory, emergency department and cardiologists. The initial undertaking of the TF-CB, which is comprised of laboratory medicine scientists, emergency medicine physicians and cardiologists, was to address two key issues pertaining to implementing high-sensitivity cardiac troponin (hs-cTn) assays in clinical practice: the 99th percentile upper reference limit (URL) and calculating serial change values in accord with the Universal Definition of AMI. The highlights of both concepts from IFCC statements are described.
KW - 99th percentile
KW - High-sensitivity cardiac troponin assays
KW - IFCC
KW - Myocardial infarction
KW - Risk stratification
UR - http://www.scopus.com/inward/record.url?scp=84924589407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924589407&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2014.08.021
DO - 10.1016/j.clinbiochem.2014.08.021
M3 - Article
C2 - 25204966
AN - SCOPUS:84924589407
SN - 0009-9120
VL - 48
SP - 201
EP - 203
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 4-5
ER -